# Audit Report: EMA Post-Authorization Lifecycle (XELJANZ)

## üìÇ Data Provenance & Integrity (European Union)
This report tracks the regulatory evolution of Xeljanz in the EU following its initial 2017 approval.

- **Source Document:** Procedural steps taken after authorisation (Xeljanz)
- **Source Agency:** European Medicines Agency (EMA)
- **SHA-256 Hash:** `2C85A88014F9A49C88F5DCBF5A1DD7F3583C580A0167159479CA6E7064399271`
- **Last Updated in Audit:** January 2026 (Reflecting EMA data up to Dec 2025)

---

## üõ°Ô∏è Significant 2025 Regulatory Actions
The following high-priority updates were captured in the 2025 EMA audit:

### 1. Safety Signal Update (Nov 2025)
- **Variation Type:** Type II (EMA/VR/0000296118)
- **Date of Opinion:** 2025-11-27
- **Action:** Update of SmPC Sections 4.4 and 4.8.
- **Key Change:** Added **Cerebral Venous Sinus Thrombosis (CVST)** as a subtype of Venous Thromboembolism (VTE) to the adverse reactions list.

### 2. Periodic Safety Update (June 2025)
- **Procedure:** PSUR/EMA/PSUR/0000248531
- **Date of Opinion:** 2025-06-05
- **Conclusion:** PRAC recommends the **maintenance of the marketing authorisation** based on the review of current safety and efficacy data.

---

## üìä Audit Insight: The "Living Document" Principle
Unlike traditional medical databases, OncoAudit (v2.0.0) tracks the **procedural history** of a drug. This EMA document proves that regulatory oversight is an ongoing process. 

**Comparative Note:**
- **Status:** The EU remains more descriptive regarding specific thromboembolism subtypes (like CVST) compared to historical baseline labels.
- **Transparency:** Every administrative change (e.g., supplier changes in Dec 2025) is logged with a specific procedural ID, ensuring full supply chain auditability.

---
*This document is part of the **OncoAudit (v2.0.0)** research series, anchored via SHA-256 for permanent record-keeping.*
